GlassScriptPrepare for your visit
Michael Martin
Hematology & Oncology · Memphis, TN · NPI 1588671085
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$31,274.04
in general payments reported to CMS, 2019-2025 · $229 in 2025
The $229 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Who reported paying
General payments only, top 6 by amount.
- Abbvie INC. $6,899.28
- Jazz Pharmaceuticals INC. $6,112.77
- Amgen INC. $4,143.20
- Agios Pharmaceuticals, INC. $3,841.03
- Celgene Corporation $2,343.13
- Beigene USA, INC. $2,168.33
Drugs and devices associated with these payments
Enhertu Orgovyx Xtandi Keytruda Verzenio Jaypirca Talzenna Opdivo Darzalex Ninlaro Opdualag Venclexta
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Michael Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/253001/michael-martin